Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

May 1, 2028

Conditions

AML, Adult

Interventions

DRUG

Decitabine

decitabine 20mg/m2 per day for consecutive 5 days

DRUG

Fludarabine Injection

fludarabine 30mg/m2 per day for consecutive 5 days

DRUG

Busulfan Injection

Busulfan 3.2mg/kg per day for consecutive 4 days

Trial Locations (1)

Ruijin Hospital, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER